Key clinical point: Preliminary data suggest novel extended half-life factor VIII (FVIII) and factor IX (FIX) products maintain higher trough levels and decrease the number of infusions in patients with hemophilia.
Major finding: Across 33 hemophilia treatment centers, extended half-life FVIII products decreased the number of infusions by 30% or greater and achieved trough levels of 3%-5% in 66%-67% of centers, respectively.
Study details: A European multinational survey of 33 hemophilia treatment centers.
Disclosures: No funding sources were reported. The authors reported financial affiliations with Alnylam, Grifols, Kedrion, Pfizer, Roche, Sanofi, Bayer, Shire, and several other companies.
Peyvandi F et al. Haemophilia. 2019 Aug 16. doi: 10.1111/hae.13834.